

Cyient DLM (CYIENTDL IN)

Rating: BUY | CMP: Rs515 | TP: Rs692

January 22, 2025

Q3FY25 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Cur	rent	Pre	vious
	FY26E	FY27E	FY26E	FY27E
Rating	В	UY	В	UY
Target Price	6	92	8	331
Sales (Rs. m)	20,094	25,765	23,306	27,862
% Chng.	(13.8)	(7.5)		
EBITDA (Rs. m)	1,929	2,731	2,470	3,121
% Chng.	(21.9)	(12.5)		
EPS (Rs.)	15.6	23.1	21.6	27.7
% Chng.	(27.5)	(16.8)		

Key Financials - Consolidated

Y/e Mar	FY24	FY25E	FY26E	FY27E
Sales (Rs. m)	11,919	15,845	20,094	25,765
EBITDA (Rs. m)	1,110	1,276	1,929	2,731
Margin (%)	9.3	8.1	9.6	10.6
PAT (Rs. m)	612	676	1,240	1,829
EPS (Rs.)	7.7	8.5	15.6	23.1
Gr. (%)	28.6	10.4	83.4	47.5
DPS (Rs.)	-	-	-	-
Yield (%)	-	-	-	-
RoE (%)	11.1	7.1	11.7	15.1
RoCE (%)	15.0	12.0	16.7	20.9
EV/Sales (x)	3.1	2.4	1.9	1.4
EV/EBITDA (x)	33.2	30.0	19.6	13.6
PE (x)	66.7	60.4	32.9	22.3
P/BV (x)	4.5	4.1	3.6	3.1

Key Data	CYIT.BO CYIENTDL IN
<u> </u>	<u> </u>

52-W High / Low	Rs.884 / Rs.506
Sensex / Nifty	76,405 / 23,155
Market Cap	Rs.41bn/ \$ 473m
Shares Outstanding	79m
3M Avg. Daily Value	Rs.170.89m

Shareholding Pattern (%)

Promoter's	52.16
Foreign	7.76
Domestic Institution	27.77
Public & Others	12.31
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(24.0)	(32.8)	(22.0)
Relative	(22.4)	(29.1)	(27.1)

Praveen Sahay

praveensahay@plindia.com | 91-22-66322369

Rahul Shah

rahulshah@plindia.com | 91-22-66322274

Disappointing results, margin contraction continues

We cut our FY25/FY26/FY27E EPS estimates significantly by 31.2%/27.5%/16.8% to factor in low margins given the ECL provision in Q3FY25, M&A expenses, and delay in order inflow from major clients. We have revised TP to Rs692 (Rs831 earlier), based on 30x FY27E earnings. CYIENTDL Q3FY25 EBITDA was much below our estimates due to higher expenses related to M&A and ECL provision, and muted order inflow. The management is in talks for 3 large deals, the benefit of which will be visible from H2FY26. Margins are guided to be flat for FY25, but are expected to improve from H2FY26. We estimate FY24-27E revenue/EBITDA/PAT CAGR of 29.3%/35.0%/44.0%, with EBITDA margin expansion of ~130bps. Maintain 'BUY'.

Revenue increases by 38.4%, adj PAT declines by 40.4%: Sales increased by 38.4% YoY to Rs4.4bn (PLe: Rs4.6bn). Aerospace/Defense/Industrial/Medtech segment grew by 13%/33%/50%/149% YoY, while Rail declined by 54% YoY. Aerospace/Defense segment contributes 22%/46% to revenue. EBITDA declined by 4.4% YoY to Rs 281mn (PLe: Rs395mn). EBITDA margins contracted by ~280bps to 6.3% (PLe: 8.5%) due to higher employee cost on account of Altek consolidation and expense credit loss (ECL) on receivables, which resulted in higher other expenses. PBT declined by 39.2% YoY to Rs150mn (PLe: Rs 344mn). PAT declined by 40.4% YoY to Rs110mn (PLe: Rs 258mn).

Con call highlights: 1) CYIENTDL is expected to grow at 30% CAGR over FY24-FY27E with a margin of +10%. 2) The business mix significantly impacts margins, with a decline in low-margin business expected in Q4 and Q1, resulting in improved Q4 margins and a near flat margin for the full year. 3) The company added 7 logos in 9MFY25. A leading global technology company focused on energy services was added in Q3. 4) CYIENTDL has formed a strategic partnership with Arcedo to establish a 500kWp rooftop solar power plant at its Mysuru facility. 5) The company has a total contract value of more than USD1bn. 6) CYIENTDL expects to secure 3 large deals, primarily from ROW, starting from FY26. 7) It reported oneoff expenses related to M&A, resulting in margin pressure. 8) ECL provision related to a domestic client resulted in a contraction in standalone margin in Q3FY25. However, the management expects a recovery in the coming quarter. 9) ROW:India revenue contribution stood at 61%:39% in Q3FY25 vs 54%:46% in Q3FY24. 10) Order book stands at Rs21.4bn, including Rs2.9bn from Altek. 11) The acquisition of Altek Electronics has diversified the company's industry base, leading to significant growth in industrial and medtech segments.



Exhibit 1: Q3FY25 result overview: Sales increase by 38.4% YoY, PAT declines by 40.4% YoY

Y/e March (Rs mn)	Q3FY25	Q3FY24	YoY gr. (%)	Q2FY25	QoQ gr. (%)	9MFY25	9MFY24	YoY gr. (%)
Net Sales	4,442	3,210	38.4	3,895	14.1	10,916	8,300	31.5
Expenditure			100					
Operating & Manufacturing Expenses	3,257	2,506	30.0	3,092	5.3	8,276	6,445	28.4
% of Net Sales	73.3	78.0		79.4		<i>7</i> 5.8	77.7	
Gross Profit	1,186	705	68.2	802	47.7	2,640	1,855	42.3
% of Net Sales	26.7	22.0	4.73	20.6		24.2	22.3	
Personnel Cost	588	306	92.3	336	<i>7</i> 5.1	1,251	817	53.2
% of Net Sales	13.2	9.5		8.6		11.5	9.8	
Other Expenses	317	105	201.7	150	110.4	591	309	91.5
% of Net Sales	<i>7</i> .1	3.3		3.9		5.4	3.7	
Total Expenditure	4,161	2,916	42.7	3,578	16.3	10,118	7,571	33.6
EBITDA	281	294	-4.4	316	-11.1	798	730	9.3
Margin (%)	6.3	9.2		8.1		7.3	8.8	
Other income	69	93	-26.5	71	-3.5	228	195	17.0
Depreciation	100	58	<i>7</i> 3.9	69	45.9	236	161	46.8
EBIT	181	237	-23.5	248	-26.9	790	764	3.4
Interest	100	83	19.9	110	-9.3	290	250	16.0
PBT	150	247	-39.2	209	-28.2	501	514	(2.7)
Total Taxes	40	63	-35.8	54	-26.1	130	130	0.2
ETR (%)	26.8	25.3		26.0		26.0	25.3	
Adj. PAT	110	184	-40.4	155	-28.9	370	385	(3.7)
Exceptional Items	-	-		-		-	-	
Reported PAT	110	184	(40.4)	155	-28.9	370	385	(3.7)

Source: Company, PL

Exhibit 2: Segmental breakup: Aerospace/Defense segment grows by 13%/33% in Q3FY25

Y/e March (Rs mn)	Q3FY25	Q3FY24	YoY gr. (%)	Q2FY25	QoQ gr. (%)	9MFY25	9MFY24	YoY gr. (%)
Revenues								
Aerospace	977	867	12.7	779	25.5	2,427	1,900	27.7
Defense	2,043	1,541	32.6	2,570	(20.5)	6,084	3,796	60.3
Industrial	578	385	49.9	273	111.8	979	1,620	(39.6)
Medtech	800	321	149.1	234	242.2	1,291	742	73.9
Rail	44	96	(53.9)	39	14.1	135	242	(44.1)
Total	4,442	3,210	38.4	3,895	14.1	10,916	8,300	31.5

Source: Company, PL



Financials

Income Statement ((Rs m)	١
--------------------	--------	---

Income Statement (Rs m)				
Y/e Mar	FY24	FY25E	FY26E	FY27E
Net Revenues	11,919	15,845	20,094	25,765
YoY gr. (%)	43.2	32.9	26.8	28.2
Cost of Goods Sold	9,200	11,892	15,191	19,478
Gross Profit	2,719	3,953	4,903	6,287
Margin (%)	22.8	24.9	24.4	24.4
Employee Cost	1,174	1,775	1,869	2,267
Other Expenses	435	902	1,105	1,288
EBITDA	1,110	1,276	1,929	2,731
YoY gr. (%)	26.5	15.0	51.1	41.6
Margin (%)	9.3	8.1	9.6	10.6
Depreciation and Amortization	223	317	348	388
EBIT	887	959	1,581	2,343
Margin (%)	7.4	6.1	7.9	9.1
Net Interest	344	369	248	264
Other Income	278	313	324	364
Profit Before Tax	821	903	1,657	2,444
Margin (%)	6.9	5.7	8.2	9.5
Total Tax	209	227	417	615
Effective tax rate (%)	25.5	25.2	25.2	25.2
Profit after tax	612	676	1,240	1,829
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	612	676	1,240	1,829
YoY gr. (%)	92.9	10.4	83.4	47.5
Margin (%)	5.1	4.3	6.2	7.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	612	676	1,240	1,829
YoY gr. (%)	92.9	10.4	83.4	47.5
Margin (%)	5.1	4.3	6.2	7.1
Other Comprehensive Income	(240)	-	-	-
Total Comprehensive Income	372	676	1,240	1,829
Equity Shares O/s (m)	79	79	79	79
EPS (Rs)	7.7	8.5	15.6	23.1

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Balance Sheet Abstract (Rs m)				
Y/e Mar	FY24	FY25E	FY26E	FY27E
Non-Current Assets				
Gross Block	2,640	4,337	4,688	5,055
Tangibles	2,498	4,148	4,448	4,748
Intangibles	142	189	240	308
Acc: Dep / Amortization	1,243	1,512	1,798	2,108
Tangibles	1,123	1,371	1,629	1,904
Intangibles	120	141	169	204
Net fixed assets	1,397	2,825	2,890	2,947
Tangibles	1,374	2,777	2,819	2,843
Intangibles	22	48	71	104
Capital Work In Progress	504	428	489	575
Goodwill	30	30	30	30
Non-Current Investments	715	715	715	715
Net Deferred tax assets	59	59	59	59
Other Non-Current Assets	69	67	67	67
Current Assets				
Investments	-	-	-	-
Inventories	4,642	6,078	7,707	9,882
Trade receivables	2,259	2,822	3,303	4,235
Cash & Bank Balance	5,366	3,409	3,931	4,586
Other Current Assets	743	885	1,038	1,221
Total Assets	16,033	17,610	20,573	24,725
Equity				
Equity Share Capital	793	793	793	793
Other Equity	8,297	9,158	10,397	12,226
Total Networth	9,090	9,951	11,190	13,019
Non-Current Liabilities				
Long Term borrowings	747	247	247	247
Provisions	106	141	179	230
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	589	589	589	589
Trade payables	3,200	4,254	5,396	6,918
Other current liabilities	3,200 1,605	4,254 1,857	5,396 2,355	6,918 3,020

Source: Company Data, PL Research



Cash Flow (Rs m)				
Y/e Mar	FY24	FY25E	FY26E	FY27E
PBT	821	903	1,657	2,444
Add. Depreciation	223	317	348	388
Add. Interest	344	369	248	264
Less Financial Other Income	278	313	324	364
Add. Other	(222)	(313)	(324)	(364)
Op. profit before WC changes	1,166	1,276	1,929	2,731
Net Changes-WC	(1,676)	(900)	(702)	(1,199)
Direct tax	(195)	227	417	615
Net cash from Op. activities	(705)	603	1,644	2,147
Capital expenditures	(338)	(1,669)	(474)	(532)
Interest / Dividend Income	107	313	324	364
Others	(4,046)	2,900	-	-
Net Cash from Invt. activities	(4,277)	1,544	(150)	(168)
Issue of share cap. / premium	6,694	-	-	-
Debt changes	(1,647)	(602)	72	119
Dividend paid	-	-	-	-
Interest paid	(192)	(369)	(248)	(264)
Others	(65)	-	-	-
Net cash from Fin. activities	4,790	(971)	(177)	(144)
Net change in cash	(193)	1,176	1,318	1,835
Free Cash Flow	(1,043)	(1,066)	1,170	1,615

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Net Revenue	3,618	2,579	3,895	4,442
YoY gr. (%)	30.5	18.8	33.4	38.4
Raw Material Expenses	2,754	1,927	3,092	3,257
Gross Profit	864	652	802	1,186
Margin (%)	23.9	25.3	20.6	26.7
EBITDA	380	200	316	281
YoY gr. (%)	19.2	-	34.4	(4.4)
Margin (%)	10.5	7.8	8.1	6.3
Depreciation / Depletion	62	67	69	100
EBIT	318	133	248	181
Margin (%)	8.8	5.2	6.4	4.1
Net Interest	94	80	110	100
Other Income	83	89	71	69
Profit before Tax	307	142	209	150
Margin (%)	8.5	5.5	5.4	3.4
Total Tax	79	36	54	40
Effective tax rate (%)	25.8	25.2	26.0	26.8
Profit after Tax	228	106	155	110
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	228	106	155	110
YoY gr. (%)	81.0	97.7	5.5	(40.4)
Margin (%)	6.3	4.1	4.0	2.5
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	228	106	155	110
YoY gr. (%)	81.0	97.7	5.5	(40.4)
Margin (%)	6.3	4.1	4.0	2.5
Other Comprehensive Income	(234)	3	(2)	1
Total Comprehensive Income	(6)	109	153	111
Avg. Shares O/s (m)	79	79	79	79
EPS (Rs)	2.9	1.4	1.9	1.4

Source: Company Data, PL Research

Ke۱	/ Fina	ncia	ı Me	trics

FY24	FY25E	FY26E	FY27E
7.7	8.5	15.6	23.1
10.5	12.5	20.0	27.9
114.6	125.5	141.1	164.2
(13.2)	(13.4)	14.8	20.4
-	-	-	-
15.0	12.0	16.7	20.9
27.4	10.0	15.8	21.0
11.1	7.1	11.7	15.1
(0.4)	(0.3)	(0.3)	(0.3)
113	107	102	102
66.7	60.4	32.9	22.3
4.5	4.1	3.6	3.1
48.9	41.1	25.7	18.4
33.2	30.0	19.6	13.6
3.1	2.4	1.9	1.4
-	-	-	-
	7.7 10.5 114.6 (13.2) - 15.0 27.4 11.1 (0.4) 113 66.7 4.5 48.9 33.2	7.7 8.5 10.5 12.5 114.6 125.5 (13.2) (13.4) 15.0 12.0 27.4 10.0 11.1 7.1 (0.4) (0.3) 113 107 66.7 60.4 4.5 4.1 48.9 41.1 33.2 30.0	7.7 8.5 15.6 10.5 12.5 20.0 114.6 125.5 141.1 (13.2) (13.4) 14.8 15.0 12.0 16.7 27.4 10.0 15.8 11.1 7.1 11.7 (0.4) (0.3) (0.3) 113 107 102 66.7 60.4 32.9 4.5 4.1 3.6 48.9 41.1 25.7 33.2 30.0 19.6

Source: Company Data, PL Research

January 22, 2025 4



Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Astral Ltd.	BUY	1,883	1,553
2	Avalon Technologies	Hold	899	938
3	Bajaj Electricals	Reduce	676	782
4	Century Plyboard (I)	Hold	811	823
5	Cera Sanitaryware	Hold	7,712	7,188
6	Crompton Greaves Consumer Electricals	BUY	536	368
7	Cyient DLM	BUY	831	645
8	Finolex Industries	Accumulate	270	233
9	Greenpanel Industries	BUY	427	361
10	Havells India	BUY	1,890	1,578
11	Kajaria Ceramics	BUY	1,545	1,061
12	Kaynes Technology India	Hold	6,085	6,971
13	KEI Industries	BUY	5,265	4,313
14	Polycab India	BUY	8,741	7,163
15	R R Kabel	BUY	2,151	1,385
16	Supreme Industries	BUY	5,040	4,022
17	Syrma SGS Technology	Hold	629	610
18	Voltas	Accumulate	1,980	1,780

PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly

January 22, 2025 5

6



ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Praveen Sahay- MBA Finance, Mr. Rahul Shah- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Praveen Sahay- MBA Finance, Mr. Rahul Shah- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com